# ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

> **NCT05830123** · PHASE2 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 170 (estimated)

## Conditions studied

- Osteosarcoma
- Sarcoma

## Interventions

- **DRUG:** HS-20093

## Key facts

- **NCT ID:** NCT05830123
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-08
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05830123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05830123, "ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05830123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*